CV: peripheral vasculopathy, SUDDEN DEATH, tachycardia.
EENT: visual disturbances.
GI: abdominal pain, anorexia, nausea.
GU: libido changes, priapism.
Metab: growth suppression, weight loss (may occur with prolonged use).
MS: RHABDOMYOLYSIS.
Neuro: twitching, behavioral disturbances, hallucinations, insomnia, mania, nervousness, thought disorder.
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Tablets
- PO (Adults and Children 6 yr): Patients not previously taking methylphenidate 2.5 mg twice daily, may be ↑ weekly as needed up to 10 mg twice daily; Patients currently taking methylphenidate starting dose is 1/2 of the methylphenidate dose, up to 10 mg twice daily.
Extended-Release Capsules
- PO (Adults): Patients not previously taking methylphenidate 10 mg once daily, may be ↑ by 10 mg up to 40 mg/day; Patients currently taking methylphenidate starting dose is 1/2 of the methylphenidate dose, up to 40 mg/day given as a single daily dose; Patients currently taking dexmethylphenidate give same daily dose as a single dose.
- PO (Children 6 yr): Patients not previously taking methylphenidate 5 mg once daily, may be ↑ by 5 mg weekly up to 30 mg/day; Patients currently taking methylphenidate starting dose is 1/2 of the methylphenidate dose, up to 30 mg/day, given as a single daily dose; Patients currently taking dexmethylphenidate give same daily dose as a single dose.
Therapeutic Classification: central nervous system stimulants
Absorption: Readily absorbed following oral administration.
Distribution: Unknown.
Metabolism/Excretion: Mostly metabolized by the liver; inactive metabolites are renally excreted.
Half-life: 2.2 hr.
(improvement in symptoms)